Quick Answer
Context Therapeutics Inc. reported Cash and Equivalents of $66.00 million for fiscal year 2025.
Context Therapeutics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $66.00M | -30.1% |
| 2024 | $94.43M | +553.5% |
| 2023 | $14.45M | -59.3% |
| 2022 | $35.50M | -28.5% |
| 2021 | $49.64M | +16976.1% |
| 2020 | $290.7K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $76.94M | -9.3% | -7.9% |
| June 30, 2025 | $83.52M | -17.7% | -6.5% |
| March 31, 2025 | $89.35M | +785.6% | -5.4% |
| December 31, 2024 | $94.43M | +553.5% | +11.4% |
| September 30, 2024 | $84.80M | +291.2% | -16.5% |
| June 30, 2024 | $101.54M | +303.9% | +906.4% |
| March 31, 2024 | $10.09M | -66.1% | -30.2% |
| December 31, 2023 | $14.45M | -59.3% | -33.3% |
- Context Therapeutics Inc. showed a decrease of -30.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Context Therapeutics Inc.’s cash and equivalents has grown by 22604.5% (from $290.7 thousand to $66.00 million).
- The most recent figure is from Context Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: